COMPUTER-AIDED DRUG DESIGN AND ITS APPLICATIONS IN CANCER RESEARCH: A REVIEW
DOI:
https://doi.org/10.22159/ijms.2024v13i2.53888Keywords:
Computer-Aided Drug Design (CADD), Cancer research, Virtual screening, Molecular dynamics (MD) simulations, Quantitative Structure-Activity Relationship (QSAR)Abstract
Computer-aided drug design (CADD) has become a crucial tool in cancer research, leveraging advanced computational techniques to accelerate drug discovery and develop targeted anticancer agents. By simulating molecular interactions and predicting the behavior of potential drug candidates, CADD aids in identifying novel compounds with enhanced specificity and reduced toxicity. Virtual screening, a key element of CADD, allows rapid assessment of thousands of compounds to target specific cancer-related proteins or pathways. Molecular dynamics simulations provide insights into protein conformational changes and their interactions with small molecules, facilitating rational drug design. Molecular docking predicts the binding affinity and orientation of ligands within protein binding sites, streamlining the identification of potential drug candidates and reducing experimental trial and error. Quantitative structure-activity relationship models quantitatively relate chemical structures to biological activities, optimizing drug candidates by refining chemical scaffolds to enhance efficacy and minimize toxicity. CADD’s impact on drug development is significant, paving the way for specialized and targeted cancer treatments, offering hope for novel medications with improved effectiveness and fewer adverse effects.
References
Del Carmen Quintal Bojórquez N, Campos MR. Traditional and novel computer-aided drug design (CADD) approaches in the anticancer drug discovery process. Curr Cancer Drug Targets 2023;23:333-45.
Sliwoski G, Kothiwale S, Meiler J, Lowe EW Jr. Computational methods in drug discovery. Pharmacol Rev 2013;66:334-95.
Baig MH, Ahmad K, Rabbani G, Danishuddin M, Choi I. Computer aided drug design and its application to the development of potential drugs for neurodegenerative disorders. Curr Neuropharmacol 2018;16:740-8.
Yu W, MacKerell AD Jr. Computer-aided drug design methods. Methods Mol Biol 2017;1520:85-106.
Rahman MM, Islam MR, Rahman F, Rahaman MS, Khan MS, Abrar S, et al. Emerging promise of computational techniques in anti-cancer research: At a glance. Bioengineering (Basel) 2022;9:335.
Mak IW, Evaniew N, Ghert M. Lost in translation: Animal models and clinical trials in cancer treatment. Am J Transl Res 2014;6:114-8.
Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: Methods for virtual ligand screening and profiling. Br J Pharmacol 2007;152:9-20.
Torres PH, Sodero AC, Jofily P, Silva-Jr FP. Key topics in molecular docking for drug design. Int J Mol Sci 2019;20:4574.
Dara S, Dhamercherla S, Jadav SS, Babu CM, Ahsan MJ. Machinelearning in drug discovery: Areview. Artif Intell Rev 2022;55:1947-99.
Niazi SK, Mariam Z. Recent advances in machine-learning-based chemoinformatics: A comprehensive review. Int J Mol Sci 2023;24:11488.
Batool M, Ahmad B, Choi S. A structure-based drug discovery paradigm. Int J Mol Sci 2019;20:2783.
Rasulev B. Recent developments in 3D QSAR and molecular docking studies of organic and nanostructures. In: Handbook of Computational Chemistry. Vol. 9. Berlin, Germany: Springer International Publishing; 2016. p. 2133-61.
Singh V, Kumar A, Gupta S. Mental health prevention and promotion-a narrative review. Front Psychiatry 2022;13:898009.
Szymański P, Markowicz M, Mikiciuk-Olasik E. Adaptation of high-throughput screening in drug discovery-toxicological screening tests. Int J Mol Sci 2012;13:427-52.
Debnath AK. Quantitative structure-activity relationship (QSAR) paradigm--Hansch era to new millennium. Mini Rev Med Chem 2001;1:187-95.
Cherkasov A, Muratov EN, Fourches D, Varnek A, Baskin II, Cronin M, et al. QSAR modeling: Where have you been? Where are you going to? J Med Chem 2014;57:4977-5010.
Zhao X, Chen M, Huang B, Ji H, Yuan M. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) studies on α(1A)-adrenergic receptor antagonists based on pharmacophore molecular alignment. Int J Mol Sci 2011;12:7022-37.
Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med 2021;9:20503121211034366. doi: 10.1177/20503121211034366
Iqbal N, Iqbal N. Imatinib: A breakthrough of targeted therapy in cancer. Chemother Res Pract 2014;2014:357027.
Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: Apowerful approach for structure-based drug discovery. Curr Comput Aided Drug Des 2011;7:146-57.
Arjmand B, Hamidpour SK, Alavi-Moghadam S, Yavari H, Shahbazbadr A, Tavirani MR, et al. Molecular docking as a therapeutic approach for targeting cancer stem cell metabolic processes. Front Pharmacol 2022;13:768556. Erratum in: Front Pharmacol 2022;13:892656.
Bravatà V, Cava C, Minafra L, Cammarata FP, Russo G, Gilardi MC, et al. Radiation-induced gene expression changes in high and low grade breast cancer cell types. Int J Mol Sci 2018;19:1084.
Urbach D, Lupien M, Karagas MR, Moore JH. Cancer heterogeneity: Origins and implications for genetic association studies. Trends Genet 2012;28:538-43.
Rajabi M, Mousa SA. The role of angiogenesis in cancer treatment. Biomedicines 2017;5:34.
Fu L, Jin W, Zhang J, Zhu L, Lu J, Zhen Y, et al. Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions. Acta Pharm Sin B 2022;12:532-57.
Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: A brief review. Adv Pharm Bull 2017;7:339-48.
Hollingsworth SA, Dror RO. Molecular dynamics simulation for all. Neuron 2018;99:1129-43.
Hospital A, Goñi JR, Orozco M, Gelpí JL. Molecular dynamics simulations: Advances and applications. Adv Appl Bioinform Chem 2015;8:37-47.
Castellani G, Buccarelli M, Arasi MB, Rossi S, Pisanu ME, Bellenghi M, et al. BRAF mutations in melanoma: Biological aspects, therapeutic implications, and circulating biomarkers. Cancers (Basel) 2023;15:4026.
Emran TB, Shahriar A, Mahmud AR, Rahman T, Abir MH, Siddiquee MF, et al. Multidrug resistance in cancer: Understanding molecular mechanisms, immunoprevention and therapeutic approaches. Front Oncol 2022;12:891652.
Sitia L, Sevieri M, Signati L, Bonizzi A, Chesi A, Mainini F, et al. HER- 2-targeted nanoparticles for breast cancer diagnosis and treatment. Cancers (Basel) 2022;14:2424.
Agu PC, Afiukwa CA, Orji OU, Ezeh EM, Ofoke IH, Ogbu CO, et al. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Sci Rep 2023;13:13398.
Pandurangan AP, Blundell TL. Prediction of impacts of mutations on protein structure and interactions: SDM, a statistical approach, and mCSM, using machine learning. Protein Sci 2020;29:247-57.
Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, et al. Advances in drug delivery systems, challenges and future directions. Heliyon 2023;9:e17488.
Zhu X, Lopes PE, Mackerell AD Jr. Recent developments and applications of the CHARMM force fields. Wiley Interdiscip Rev Comput Mol Sci 2012;2:167-85.
Published
How to Cite
Issue
Section
Copyright (c) 2025 KETAN CHANDRA, SARANSH SHARMA, MONIKA AHLAWAT, SUNIDHI CHAUHAN, ARCHIT SHARMA
This work is licensed under a Creative Commons Attribution 4.0 International License.
